12,382 Shares in MaxCyte, Inc. $MXCT Purchased by May Hill Capital LLC

May Hill Capital LLC purchased a new position in MaxCyte, Inc. (NASDAQ:MXCT) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 12,382 shares of the company’s stock, valued at approximately $27,000.

Other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC increased its stake in shares of MaxCyte by 7,935.4% in the 2nd quarter. Farther Finance Advisors LLC now owns 11,812 shares of the company’s stock worth $26,000 after acquiring an additional 11,665 shares in the last quarter. CWM LLC increased its stake in shares of MaxCyte by 92.7% in the 2nd quarter. CWM LLC now owns 12,132 shares of the company’s stock worth $26,000 after acquiring an additional 5,836 shares in the last quarter. Moors & Cabot Inc. increased its stake in shares of MaxCyte by 34.4% in the 1st quarter. Moors & Cabot Inc. now owns 17,708 shares of the company’s stock worth $48,000 after acquiring an additional 4,528 shares in the last quarter. New York State Common Retirement Fund increased its stake in shares of MaxCyte by 131.4% in the 1st quarter. New York State Common Retirement Fund now owns 21,837 shares of the company’s stock worth $60,000 after acquiring an additional 12,400 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in MaxCyte during the 1st quarter valued at about $143,000. 68.81% of the stock is currently owned by institutional investors.

MaxCyte Stock Up 0.6%

Shares of NASDAQ MXCT opened at $1.55 on Wednesday. The firm’s 50-day moving average price is $1.54 and its 200-day moving average price is $1.99. The company has a market cap of $165.25 million, a PE ratio of -3.60 and a beta of 1.23. MaxCyte, Inc. has a 52-week low of $1.26 and a 52-week high of $5.20.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The company had revenue of $8.51 million for the quarter, compared to analysts’ expectations of $9.57 million. MaxCyte had a negative net margin of 125.22% and a negative return on equity of 22.12%. As a group, equities research analysts anticipate that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on MXCT shares. William Blair lowered shares of MaxCyte from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 7th. Wall Street Zen lowered shares of MaxCyte from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Weiss Ratings restated a “sell (d-)” rating on shares of MaxCyte in a research note on Tuesday, October 14th. Stephens started coverage on shares of MaxCyte in a research note on Tuesday, July 22nd. They set an “overweight” rating and a $6.00 price objective for the company. Finally, BTIG Research restated a “neutral” rating on shares of MaxCyte in a research note on Monday, August 11th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, MaxCyte presently has an average rating of “Hold” and an average price target of $7.00.

Insider Buying and Selling

In other MaxCyte news, Director Richard Douglas acquired 80,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 13th. The shares were bought at an average price of $1.39 per share, with a total value of $111,200.00. Following the completion of the acquisition, the director owned 230,577 shares in the company, valued at $320,502.03. This represents a 53.13% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Maher Masoud acquired 75,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 13th. The stock was acquired at an average cost of $1.37 per share, for a total transaction of $102,750.00. Following the acquisition, the chief executive officer owned 175,000 shares of the company’s stock, valued at $239,750. The trade was a 75.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 355,000 shares of company stock valued at $479,950 in the last 90 days. 3.30% of the stock is owned by insiders.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.